Skip to main content
Top
Published in: Inflammation 6/2010

01-12-2010

The ApoB/ApoA1 Ratio is Associated with Metabolic Syndrome and its Components in a Chinese Population

Authors: Li Zhong, Qifu Li, Yuanjuan Jiang, Dan Cheng, Zhoujun Liu, Bangqiong Wang, Rong Luo, Qingfeng Cheng, Hua Qing

Published in: Inflammation | Issue 6/2010

Login to get access

Abstract

In this study, we assessed whether the apolipoprotein B/apolipoprotein A1 ratio (ApoB/ApoA1) is related to metabolic syndrome (MS) and its components in an urban Chinese population. A total of 709 community residents were enrolled. Metabolic syndrome was defined according to the International Diabetes Federation definition in 2005. The high ApoB/ApoA1 group was defined as the gender-specific upper quartile of the ApoB/ApoA1 ratio. Insulin resistance (IR) was defined as the upper quartile of Homa-IR. The ApoB/ApoA1 ratio was significantly higher in subjects with MS, compared to those without (p < 0.05). After adjusting for age and gender, subjects with MS (odds ratio [OR] = 3.5) or IR (OR = 2.3) were more likely to be in the high ApoB/ApoA1 group. The ApoB/ApoA1 ratio increased significantly as the number of MS components increased (p < 0.05). Taken together, these data demonstrate that the ApoB/ApoA1 ratio is strongly associated with MS and its components in an urban Chinese population.
Literature
1.
go back to reference Alberti, K.G., P. Zimmet, J. Shaw, and IDF Epidemiology Task Force Consensus Group. 2005. The metabolic syndrome—a new worldwide definition. Lancet 366: 1059–1062.CrossRefPubMed Alberti, K.G., P. Zimmet, J. Shaw, and IDF Epidemiology Task Force Consensus Group. 2005. The metabolic syndrome—a new worldwide definition. Lancet 366: 1059–1062.CrossRefPubMed
3.
go back to reference Elovson, J., J.E. Chatterton, G.T. Bell, V.N. Schumaker, M.A. Reuben, D.L. Puppione, J.R. Reeve, and N.L. Young. 1988. Plasma very low density lipoproteins contain a single molecule of apolipoprotein B. Journal of Lipid Research 29: 1461–1473.PubMed Elovson, J., J.E. Chatterton, G.T. Bell, V.N. Schumaker, M.A. Reuben, D.L. Puppione, J.R. Reeve, and N.L. Young. 1988. Plasma very low density lipoproteins contain a single molecule of apolipoprotein B. Journal of Lipid Research 29: 1461–1473.PubMed
4.
go back to reference Walldius, G., I. Jungner, A.H. Aastveit, I. Holme, C.D. Furberg, and A.D. Sniderman. 2004. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clinical Chemistry and Laboratory Medicine 42: 1355–1363.CrossRefPubMed Walldius, G., I. Jungner, A.H. Aastveit, I. Holme, C.D. Furberg, and A.D. Sniderman. 2004. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clinical Chemistry and Laboratory Medicine 42: 1355–1363.CrossRefPubMed
5.
go back to reference Walldius, G., and I. Jungner. 2006. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy—a review of the evidence. Journal of Internal Medicine 259: 493–519.CrossRefPubMed Walldius, G., and I. Jungner. 2006. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy—a review of the evidence. Journal of Internal Medicine 259: 493–519.CrossRefPubMed
6.
go back to reference Walldius, G., I. Jungner, I. Holme, A.H. Aastveit, W. Kolar, and E. Steiner. 2001. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358: 2026–2033.CrossRefPubMed Walldius, G., I. Jungner, I. Holme, A.H. Aastveit, W. Kolar, and E. Steiner. 2001. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358: 2026–2033.CrossRefPubMed
7.
go back to reference Yusuf, S., S. Hawken, S. Ounpuu, T. Dans, A. Avezum, F. Lanas, M. McQueen, A. Budaj, P. Pais, J. Varigos, L. Lisheng, and INTERHEART Study Investigators. 2004. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364: 937–952.CrossRefPubMed Yusuf, S., S. Hawken, S. Ounpuu, T. Dans, A. Avezum, F. Lanas, M. McQueen, A. Budaj, P. Pais, J. Varigos, L. Lisheng, and INTERHEART Study Investigators. 2004. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364: 937–952.CrossRefPubMed
8.
go back to reference van der Steeg, W.A., S.M. Boekholdt, E.A. Stein, K. El-Harchaoui, E.S. Stroes, M.S. Sandhu, N.J. Wareham, J.W. Jukema, R. Luben, A.H. Zwinderman, J.J. Kastelein, and K.T. Khaw. 2007. Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. Annals of Internal Medicine 146: 640–648.PubMed van der Steeg, W.A., S.M. Boekholdt, E.A. Stein, K. El-Harchaoui, E.S. Stroes, M.S. Sandhu, N.J. Wareham, J.W. Jukema, R. Luben, A.H. Zwinderman, J.J. Kastelein, and K.T. Khaw. 2007. Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. Annals of Internal Medicine 146: 640–648.PubMed
9.
go back to reference Dunder, K., L. Lind, B. Zethelius, L. Berglund, and H. Lithell. 2004. Evaluation of a scoring scheme, including proinsulin and the apolipoprotein B/apolipoprotein A1 ratio, for the risk of acute coronary events in middle-aged men: Uppsala Longitudinal Study of Adult Men (ULSAM). American Heart Journal 148: 596–601.CrossRefPubMed Dunder, K., L. Lind, B. Zethelius, L. Berglund, and H. Lithell. 2004. Evaluation of a scoring scheme, including proinsulin and the apolipoprotein B/apolipoprotein A1 ratio, for the risk of acute coronary events in middle-aged men: Uppsala Longitudinal Study of Adult Men (ULSAM). American Heart Journal 148: 596–601.CrossRefPubMed
10.
go back to reference Meisinger, C., H. Loewel, W. Mraz, and W. Koenig. 2005. Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study. European Heart Journal 26: 271–278.CrossRefPubMed Meisinger, C., H. Loewel, W. Mraz, and W. Koenig. 2005. Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study. European Heart Journal 26: 271–278.CrossRefPubMed
11.
go back to reference Sierra-Johnson, J., A. Romero-Corral, V.K. Somers, F. Lopez-Jimenez, G. Walldius, A. Hamsten, M.L. Hellénius, and R.M. Fisher. 2007. ApoB/apoA-I ratio: an independent predictor of insulin resistance in US non-diabetic subjects. European Heart Journal 28: 2637–2643.CrossRefPubMed Sierra-Johnson, J., A. Romero-Corral, V.K. Somers, F. Lopez-Jimenez, G. Walldius, A. Hamsten, M.L. Hellénius, and R.M. Fisher. 2007. ApoB/apoA-I ratio: an independent predictor of insulin resistance in US non-diabetic subjects. European Heart Journal 28: 2637–2643.CrossRefPubMed
12.
go back to reference Matthews, D.R., J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, and R.C. Turner. 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412–419.CrossRefPubMed Matthews, D.R., J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, and R.C. Turner. 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412–419.CrossRefPubMed
13.
go back to reference Relimpio, F., F. Losada, A. Pumar, M.A. Mangas, F. Morales, and R. Astorga. 2002. Relationships of apolipoprotein B(100) with the metabolic syndrome in type 2 diabetes mellitus. Diabetes Research and Clinical Practice 57: 199–207.CrossRefPubMed Relimpio, F., F. Losada, A. Pumar, M.A. Mangas, F. Morales, and R. Astorga. 2002. Relationships of apolipoprotein B(100) with the metabolic syndrome in type 2 diabetes mellitus. Diabetes Research and Clinical Practice 57: 199–207.CrossRefPubMed
14.
go back to reference Muntner, P., J. He, J. Chen, V. Fonseca, and P.K. Whelton. 2004. Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Annals of Epidemiology 14: 686–695.CrossRefPubMed Muntner, P., J. He, J. Chen, V. Fonseca, and P.K. Whelton. 2004. Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Annals of Epidemiology 14: 686–695.CrossRefPubMed
15.
go back to reference Onat, A., G. Can, G. Hergenç, M. Yazici, A. Karabulut, and S. Albayrak. 2007. Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension and diabetes, independent of markers of central obesity and inflammation. International Journal of Obesity 31: 1119–1125.CrossRefPubMed Onat, A., G. Can, G. Hergenç, M. Yazici, A. Karabulut, and S. Albayrak. 2007. Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension and diabetes, independent of markers of central obesity and inflammation. International Journal of Obesity 31: 1119–1125.CrossRefPubMed
16.
go back to reference Wallenfeldt, K., L. Bokemark, J. Wikstrand, J. Hulthe, and B. Fagerberg. 2004. Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men. Stroke 35: 2248–2252.CrossRefPubMed Wallenfeldt, K., L. Bokemark, J. Wikstrand, J. Hulthe, and B. Fagerberg. 2004. Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men. Stroke 35: 2248–2252.CrossRefPubMed
17.
go back to reference Lind, L., B. Vessby, and J. Sundström. 2006. The apolipoprotein B/AI ratio and the metabolic syndrome independently predict risk for myocardial infarction in middle-aged men. Arteriosclerosis, Thrombosis, and Vascular Biology 26: 406–410.CrossRefPubMed Lind, L., B. Vessby, and J. Sundström. 2006. The apolipoprotein B/AI ratio and the metabolic syndrome independently predict risk for myocardial infarction in middle-aged men. Arteriosclerosis, Thrombosis, and Vascular Biology 26: 406–410.CrossRefPubMed
18.
go back to reference Sierra-Johnson, J., V.K. Somers, F.H. Kuniyoshi, C.A. Garza, W.L. Isley, A.S. Gami, and F. Lopez-Jimenez. 2006. Comparison of apolipoprotein-B/apolipoprotein-AI in subjects with versus without the metabolic syndrome. American Journal of Cardiology 98: 1369–1373.CrossRefPubMed Sierra-Johnson, J., V.K. Somers, F.H. Kuniyoshi, C.A. Garza, W.L. Isley, A.S. Gami, and F. Lopez-Jimenez. 2006. Comparison of apolipoprotein-B/apolipoprotein-AI in subjects with versus without the metabolic syndrome. American Journal of Cardiology 98: 1369–1373.CrossRefPubMed
19.
go back to reference Zhao, W.H., J. Zhang, Y. You, Q.Q. Man, H. Li, C.R. Wang, Y. Zhai, Y. Li, S.G. Jin, and X.G. Yang. 2005. Epidemiologic characteristics of dyslipidemia in people aged 18 years and over in China. Zhonghua Yu Fang Yi Xue Za Zhi. 39: 306–310 (In Chinese).PubMed Zhao, W.H., J. Zhang, Y. You, Q.Q. Man, H. Li, C.R. Wang, Y. Zhai, Y. Li, S.G. Jin, and X.G. Yang. 2005. Epidemiologic characteristics of dyslipidemia in people aged 18 years and over in China. Zhonghua Yu Fang Yi Xue Za Zhi. 39: 306–310 (In Chinese).PubMed
Metadata
Title
The ApoB/ApoA1 Ratio is Associated with Metabolic Syndrome and its Components in a Chinese Population
Authors
Li Zhong
Qifu Li
Yuanjuan Jiang
Dan Cheng
Zhoujun Liu
Bangqiong Wang
Rong Luo
Qingfeng Cheng
Hua Qing
Publication date
01-12-2010
Publisher
Springer US
Published in
Inflammation / Issue 6/2010
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-010-9193-4

Other articles of this Issue 6/2010

Inflammation 6/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.